Defining molecular initiating events in the adverse outcome pathway framework for risk assessment

Chemical Research in Toxicology

Volumn 27, Issue 12, 2014, Pages 2100-2112

  Allen, Timothy E H ^a   Goodman, Jonathan M ^a   Gutsell, Steve ^b   Russell, Paul J ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNILEVER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CHLORPROMAZINE; KOJIC ACID; METHOTREXATE; PARACETAMOL; VALPROIC ACID;

ADVERSE OUTCOME; ARTICLE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; CONCEPTUAL FRAMEWORK; DNA SYNTHESIS INHIBITION; DOWN REGULATION; ECOTOXICOLOGY; HEART VENTRICLE ARRHYTHMIA; HUMAN; IN VITRO STUDY; LIPIDOSIS; MITOCHONDRIAL MEMBRANE; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; MOLECULAR INITIATING EVENT; MOLECULAR MODEL; ORAL MUCOSITIS; OXIDATION; OXIDATIVE STRESS; PIMEPHALES PROMELAS; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SULFOXIDATION;

EID: 84918503651     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx500345j     Document Type: Article

References (166)

1. OECD (2012), Proposal for a Template, and Guidance on Developing and Assessing the Completeness of Adverse Outcome Pathways, Appendix I, Collection of Working Definitions, http:/www.oecd.org/chemicalsafety/testingofchemicals/49963576.pdf.
2. Ankley, G. T., Bennett, R. S., Erickson, R. J., Hoff, D. J., Hornung, M. W., Johnson, R. D., Mount, D. R., Nichols, J. W., Russom, C. L., Schmieder, P. K., Serrrano, J. a, Tietge, J. E., and Villeneuve, D. L. (2010) Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 29, 730-741.
3. European Molecular Biology Laboratory-European Bioinformatics Institute, ChEMBL database, https://www.ebi.ac.uk/chembl/.
4. Bender, A. (2010) Databases: Compound bioactivities go public. Nat. Chem. Biol. 6, 309-309.
5. Wang, Y., Xiao, J., Suzek, T. O., Zhang, J., Wang, J., and Bryant, S. H. (2009) PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37, W623-W633.
6. Seiler, K. P., George, G. a, Happ, M. P., Bodycombe, N. E., Carrinski, H. a, Norton, S., Brudz, S., Sullivan, J. P., Muhlich, J., Serrano, M., Ferraiolo, P., Tolliday, N. J., Schreiber, S. L., and Clemons, P. a. (2008) ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res. 36, D351-D359.
7. Committee on Toxicity Testing and Assessment of Environmental Agents, National Research Council (2007) Toxicology Testing in the 21st Century: A Vision and a Strategy, National Academies Press, Washington, DC.
8. Hartung, T. (2009) Toxicology for the twenty-first century. Nature 460, 208-212.
9. Leist, M., Hartung, T., and Nicotera, P. (2008) The Dawning of a New Age of Toxicology. ALTEX 25, 103-114.
10. Hartung, T. (2008) Food for thought... on animal tests. ALTEX 25, 3-16.
11. Schardein, J. L., Schwetz, B. A., and Kenel, M. F. (1985) Species Sensitivities and Prediction of Tetratogenic Potential. Environ. Health Perspect. 61, 55-67.
12. Gottmann, E., Kramer, S., Pfahringer, B., and Helma, C. (2001) Data quality in predictive toxicology: reproducibility of rodent carcinogenicity experiments. Environ. Health Perspect. 109, 509-514.
13. Smith, R. (2001) Animal research: the need for a middle ground. Br. Med. J. 322, 248-249.
14. Hartung, T. (2009) A Toxicology for the 21st Century - Mapping the Road Ahead. Toxicol. Sci. 109, 18-23.
15. Andersen, M. E., Clewell, H. J., Gargas, M. L., Smith, F. A., and Reitz, R. H. (1987) Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. Toxicol. Appl. Pharmacol. 87, 185-205.
16. Sexton, K., Reiter, L. W., and Zenick, H. (1995) Research to strengthen the scientific basis for health risk assessment: a survey of the context and rationale for mechanistically based methods and models. Toxicology 102 , 3-20.
17. Aardema, M. J., and MacGregor, J. T. (2002) Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat. Res. 499, 13-25.
18. MacGregor, J. T. (2003) The future of regulatory toxicology: impact of the biotechnology revolution. Toxicol. Sci. 75, 236-248.
19. Pognan, F. (2004) Genomics, proteomics and metabonomics in toxicology: hopefully not "fashionomics". Pharmacogenomics 5, 879-893.
20. Kitano, H. (2002) Systems biology: a brief overview. Science 295, 1662-1664.
21. Henry, C. J. (2003) Evolution of Toxicology for Risk Assessment. Int. J. Toxicol. 22, 3-7.
22. Teubner, W., Mehling, A., Schuster, P. X., Guth, K., Worth, A., Burton, J., van Ravenzwaay, B., and Landsiedel, R. (2013) Computer models versus reality: how well do in silico models currently predict the sensitization potential of a substance. Regul. Toxicol. Pharmacol. 67, 468-485.
23. Westerink, R. H. S. (2013) Do we really want to REACH out to in vitro? Neurotoxicology 39, 169-172.
24. Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., Dearden, J., Gramatica, P., Martin, Y. C., Todeschini, R., Consonni, V., Kuz'min, V. E., Cramer, R., Benigni, R., Yang, C., Rathman, J., Terfloth, L., Gasteiger, J., Richard, A., and Tropsha, A. (2014) QSAR Modeling: Where Have You Been? Where Are You Going To? J. Med. Chem. 57, 4977-5010.
25. Auer, C. M., Nabholz, J. V., and Karl, P. (1990) Mode of Action and the Assessment of Chemical Hazards in the Presence of Limited Data: Use of Structure-Activity Relationships (SAR) under TSCA, Section 5. Environ. Health Perspect. 87, 183-197.
26. Verhaar, H. J. M., van Leeuwen, C. J., and Hermans, J. L. M. (1992) Classifying environmental pollutants. 1: Structure-activity relationships for prediction of aquatic toxicity. Chemosphere 25, 471-491.
27. Russom, C. L., Bradbury, S. P., Broderius, S. J., Hammermeister, D. E., and Drummond, R. A. (1997) Predicting modes of toxic action from chemical structure: acute toxicity in the fathead minnow (Pimephales promelas). Environ. Toxicol. Chem. 16, 948-967.
28. Piechota, P., Cronin, M. T. D., Hewitt, M., and Madden, J. C. (2013) Pragmatic approaches to using computational methods to predict xenobiotic metabolism. J. Chem. Inf. Model. 53, 1282-1293.
29. Marchant, C. A., Briggs, K. A., and Long, A. (2008) In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic. Toxicol. Mech. Methods 18, 177-187.
30. Carlsson, L., Spjuth, O., Adams, S., Glen, R. C., and Boyer, S. (2010) Use of historic metabolic biotransformation data as a means of anticipating metabolic sites using MetaPrint2D and Bioclipse. BMC Bioinf. 11, 1-7.
31. Benfenati, E., Benigni, R., Demarini, D. M., Helma, C., Kirkland, D., Martin, T. M., Mazzatorta, P., Ouédraogo-Arras, G., Richard, a M., Schilter, B., Schoonen, W. G. E. J., Snyder, R. D., and Yang, C. (2009) Predictive models for carcinogenicity and mutagenicity: frameworks, state-of-the-art, and perspectives. J. Environ. Sci. Health 27, 57-90.
32. Bakhtyari, N. G., Raitano, G., Benfenatif, E., Martin, T., and Young, D. (2013) Comparison of In Silico Models for prediction of Mutagenicity. J. Environ. Sci. Health 31, 45-66.
33. Höfer, T., Gerner, I., Gundert-Remy, U., Liebsch, M., Schulte, A., Spielmann, H., Vogel, R., and Wettig, K. (2004) Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation. Arch. Toxicol. 78, 549-564.
34. Gutsell, S., and Russell, P. (2013) The role of chemistry in developing understanding of adverse outcome pathways and their application in risk assessment. Toxicol. Res. 2, 299-307.
35. Van den Hof, W. F. P. M., Coonen, M. L. J., van Herwijnen, M., Brauers, K., Wodzig, W. K. W. H., van Delft, Joost, H, M., and Kleinjans, J. C. S. (2013) Classification of Hepatotoxicants Using HepG2 Cells: A Proof of Principle Study. Chem. Res. Toxicol. 27, 433-442.
36. Martin, T. M., Grulke, C. M., Young, D. M., Russom, C. L., Wang, N. Y., Jackson, C. R., and Barron, M. G. (2013) Prediction of aquatic toxicity mode of action using linear discriminant and random forest models. J. Chem. Inf. Model. 53 , 2229-2239.
37. Maxwell, G., MacKay, C., Cubberley, R., Davies, M., Gellatly, N., Glavin, S., Gouin, T., Jacquoilleot, S., Moore, C., Pendlington, R., Saib, O., Sheffield, D., Stark, R., and Summerfield, V. (2014) Applying the skin sensitisation adverse outcome pathway (AOP) to quantitative risk assessment. Toxicol. Vitr. 28, 8-12.
38. Yang, C., Arvidson, K., Richard, A., Worth, A., Tarkhov, A., Ringeissen, S., Marusczyk, J., Gasteiger, J., Rathman, J., and Schwab, C. (2014) Chemotypes and Chemotyper: A new structural representation standard to include atomic/bond properties into structural alerts for toxicity effects and mechanisms, http://www.epa.gov/ncct/download-files/sot/posters/2013/SOT2013-poster-Chemotype- final.pdf.
39. Nelms, M. D., Ates, G., Madden, J. C., Vinken, M., Cronin, M. T. D., Rogiers, V., and Enoch, S. J. (2014) Proposal of an in silico profiler for categorisation of repeat dose toxicity data of hair dyes. Arch. Toxicol., DOI: 10.1007/s00204-014-1277-8.
40. Tsakovska, I., Al Sharif, M., Alov, P., Diukendjieva, A., Fioravanzo, E., Cronin, M. T. D., and Pajeva, I. (2014) Molecular modelling study of the PPAR γ receptor in relation to the mode of action/adverse outcome pathway framework for liver steatosis. Int. J. Mol. Sci. 15, 7651-7666.
41. European Commission Institute for Health and Consumer Protection, AOP Wiki, https://aopkb.org/aopwiki/index.php/Main-Page.
42. Organisation for Economic Co-operation and Development (2011) Report of the Workshop on Using Mechanistic Information in Forming Chemical Categories, OECD Environment, Health and Safety Publications, Series on Testing and Assessment No. 138, OECD, Paris, ENV/JM/MONO(2011)8.
43. Villeneuve, D. L., and Garcia-Reyero, N. (2011) Vision & strategy: Predictive Ecotoxicology in the 21st century. Environ. Toxicol. Chem. 30, 1-8.
44. Allen, T. E. H., Goodman, J. M., Gutsell, S., and Russell, P. (2013) MIE Database, unpublished data.
45. Andersen, M. E., Dennison, J. E., Thomas, R. S., and Conolly, R. B. (2005) New directions in incidence-dose modeling. Trends Biotechnol. 23, 122-127.
46. Black, M. (1984) Acetaminophen Hepatotoxicity. Annu. Rev. Med. 35, 577-593.
47. Manyike, P. T., Kharasch, E. D., Kalhorn, T. F., and Slattery, J. T. (2000) Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin. Pharmacol. Ther. 67, 275-282.
48. Albano, E., Rundgren, M., Harvison, P. J., Nelson, S. D., and Moldeus, P. (1985) Mechanisms of N-Acetyl-p-benzoquinone imine cytotoxicity. Mol. Pharmacol. 28, 306-311.
49. McGill, M. R., Yan, H.-M., Ramachandran, A., Murray, G. J., Rollins, D. E., and Jaeschke, H. (2011) HepaRG cells: a human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 53, 974-982.
50. Jaeschke, H., McGill, M. R., Williams, C. D., and Ramachandran, A. (2011) Current issues with acetaminophen hepatotoxicity - a clinically relevant model to test the efficacy of natural products. Life Sci. 88, 737-745.
51. Liu, X., Van Vleet, T., and Schnellmann, R. G. (2004) The role of calpain in oncotic cell death. Annu. Rev. Pharmacol. Toxicol. 44 , 349-370.
52. Jaeschke, H., and Bajt, M. L. (2006) Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol. Sci. 89, 31-41.
53. Hanawa, N., Shinohara, M., Saberi, B., Gaarde, W. A., Han, D., and Kaplowitz, N. (2008) Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J. Biol. Chem. 283, 13565-13577.
54. Adams, M. L., Pierce, R. H., Vail, M. E., White, C. C., Tonge, R. P., Kavanagh, T. J., Fausto, N., Nelson, S. D., and Bruschi, S. A. (2001) Enhanced acetaminophen hepatotoxicity in transgenic mice overexpressing BCL-2. Mol. Pharmacol. 60, 907-915.
55. Waldhauser, K. M., Török, M., Ha, H.-R., Thomet, U., Konrad, D., Brecht, K., Follath, F., and Krähenbühl, S. (2006) Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J. Pharmacol. Exp. Ther. 319, 1413-1423.
56. Kaufmann, P., Török, M., Hänni, A., Roberts, P., Gasser, R., and Krähenbühl, S. (2005) Mechanisms of benzarone and benzbromaroneinduced hepatic toxicity. Hepatology 41, 925-935.
57. Wendel, A., Feuerstein, S., and Konz, K.-H. (1979) Acute Paracetamol intoxication of Starved Mice leads to Lipid Peroxidation in vivo. Biochem. Pharmacol. 28, 2051-2055.
58. Limaye, P. B., Apte, U. M., Shankar, K., Bucci, T. J., Warbritton, A., and Mehendale, H. M. (2003) Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants. Toxicol. Appl. Pharmacol. 191, 211-226.
59. McGill, M. R., Sharpe, M. R., Williams, C. D., Taha, M., Curry, S. C., and Jaeschke, H. (2012) The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J. Clin. Invest. 122, 1574-1583.
60. Van Loo, G., Schotte, P., van Gurp, M., Demol, H., Hoorelbeke, B., Gevaert, K., Rodriguez, I., Ruiz-Carrillo, A., Vandekerckhove, J., Declercq, W., Beyaert, R., and Vandenabeele, P. (2001) Endonuclease G: a mitochondrial protein released in apoptosis and involved in caspase-independent DNA degradation. Cell Death Differ. 8, 1136-1142.
61. Susin, S. A., Daugas, E., Ravagnan, L., Samejima, K., Zamzami, N., Loeffler, M., Costantini, P., Ferri, K. F., Irinopoulou, T., Prévost, M. C., Brothers, G., Mak, T. W., Penninger, J., Earnshaw, W. C., and Kroemer, G. (2000) Two distinct pathways leading to nuclear apoptosis. J. Exp. Med. 192, 571-580.
62. Willett, C., Rae, J. C., Goyak, K. O., Minsavage, G., Westmoreland, C., Andersen, M., Avigan, M., Duche, D., Hartung, T., Jaeschke, H., Kleensang, A., Landesmann, B., Toole, C., Rowan, A., Schultz, T., Seed, J., Senior, J., Shah, I., Subramanian, K., Vinken, M., and Watkins, P. (2014) Building Shared Experience to Advance Practical Application of Pathway-Based Toxicology: Liver Toxicity Mode-of-Action. ALTEX, DOI: 10.14573/altex.1401281.
63. Reasor, M. J., and Kacew, S. (1996) An Evaluation of Possible Mechanisms Underlying Amiodarone-Induced Pulmonary Toxicity. Exp. Biol. Med. 212, 297-304.
64. Range, F. T., Hilker, E., Breithardt, G., Buerke, B., and Lebiedz, P. (2013) Amiodarone-Induced Pulmonary Toxicity-A Fatal Case Report and Literature Review. Cardiovasc. Drugs Ther. 27, 247-254.
65. Martin, W. J., and Rosenow, C. (1988) Amiodarone pulmonary toxicity recognition and pathogenesis (part 2). Chest 93 , 1242-1248.
66. Liu, F. L., Cohen, R. D., Downar, E., Butany, J. W., Edelson, J. D., and Rebuck, A. S. (1986) Amiodarone pulmonary toxicity: functional and ultrastructural evaluation. Thorax 41, 100-105.
67. Dusman, R. E., Stanton, M. S., Miles, W. M., Klein, L. S., Zipes, D. P., Fineberg, N. S., and Heger, J. J. (1990) Clinical features of amiodarone-induced pulmonary toxicity. Circulation 82, 51-59.
68. Rakita, L., Sobol, S. M., Mostow, N., and Vrobel, T. (1983) Amiodarone pulmonary toxicity. Am. Heart J. 106, 906-916.
69. Martin, W. J., and Rosenow, E. C. (1988) Amiodarone pulmonary toxicity recognition and pathogenesis (part 1). Chest 93 , 1067-1075.
70. Choi, I.-S., Kim, B.-S., Cho, K.-S., Park, J.-C., Jang, M.-H., Shin, M.-C., Jung, S.-B., Chung, J.-H., and Kim, C.-J. (2002) Amiodarone induces apoptosis in L-132 human lung epithelial cell line. Toxicol. Lett. 132, 47-55.
71. Bargout, R., Jankov, A., Dincer, E., Wang, R., Komodromos, T., Ibarra-Sunga, O., Filippatos, G., and Uhal, B. D. (2000) Amiodarone induces apoptosis of human and rat alveolar epithelial cells in vitro. Am. J. Physiol.: Lung Cell. Mol. Physiol. 278, 1039-1044.
72. Di Matola, T., D'Ascoli, F., Fenzi, G., Rossi, G., Martino, E., Bogazzi, F., and Vitale, M. (2000) Amiodarone induces cytochrome c release and apoptosis through an iodine-independent mechanism. J. Clin. Endocrinol. Metab. 85, 4323-4330.
73. Heath, M. F., Costa-Jussà, F. R., Jacobs, J. M., and Jacobson, W. (1985) The induction of pulmonary phospholipidosis and the inhibition of lysosomal phospholipases by amiodarone. Br. J. Exp. Pathol. 66, 391-397.
74. Anderson, N., and Borlak, J. (2006) Drug-Induced Phospholipidosis. FEBS Lett. 580, 5533-5540.
75. Kodavanti, U. P., and Mehendale, H. M. (1990) Cationic Amphiphilic Drugs and Phospholipid Storage Disorder. Pharmacol. Rev. 42, 327-354.
76. Reasor, M. J., and Kacew, S. (2001) Drug-Induced Phospholipidosis: Are There Functional Consequences? Exp. Biol. Med. 226, 825-830.
77. Sawada, H., Takami, K., and Asahi, S. (2005) A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 83, 282-292.
78. Joshi, U. M., Kodavanti, P. R. S., Coudert, B., Dwyer, T. M., and Mehendale, H. M. (1988) Types of Interaction of Amphiphilic Phospholipid Vesicles. J. Pharmacol. Exp. Ther. 246, 150-157.
79. Joshi, U. M., Rao, P., Kodavanti, S., Lockard, V. G., and Mehendale, H. M. (1989) Fluorescence studies on binding of amphiphilic drugs to isolated lamellar bodies: relevance to phospholipidosis. Biochim. Biophys. Acta 1004, 309-320.
80. Halliwell, W. H. (1997) Cationic Amphiphilic Drug-Induced Phospholipidosis. Toxicol. Pathol. 25, 53-60.
81. Kennedy, J. A., Unger, S. A., and Horowitz, J. D. (1996) Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem. Pharmacol. 52, 273-280.
82. Spaniol, M., Bracher, R., Ha, H. R., Follath, F., and Krähenbühl, S. (2001) Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. J. Hepatol. 35, 628-636.
83. Fromenty, B., and Pessayre, D. (1995) Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol. Ther. 67, 101-154.
84. Grattagliano, I., Bonfrate, L., Diogo, C. V., Wang, H. H., Wang, D. Q. H., and Portincasa, P. (2009) Biochemical mechanisms in druginduced liver injury: Certainties and doubts. World J. Gastroenterol. 15, 4865-4876.
85. Fromenty, B., Fisch, C., Labbe, G., Degott, C., Deschamps, D., Berson, A., Letteron, P., and Pessayre, D. (1990) Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J. Pharmacol. Exp. Ther. 255, 1371-1376.
86. Teresa Donato, M., Martínez-Romero, A., Jiménez, N., Negro, A., Herrera, G., Castell, J. V., O'Connor, J.-E., and Gómez-Lechón, M. J. (2009) Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem. Biol. Interact. 181, 417-423.
87. Lettéron, P., Sutton, A., Mansouri, A., Fromenty, B., and Pessayre, D. (2003) Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 38, 133-140.
88. Hautekeete, M. L., Degott, C., and Benhamou, J. P. (1990) Microvesicular steatosis of the liver. Acta Clin. Belg. 45, 311-326.
89. Serviddio, G., Bellanti, F., Giudetti, A. M., Gnoni, G. V., Capitanio, N., Tamborra, R., Romano, A. D., Quinto, M., Blonda, M., Vendemiale, G., and Altomare, E. (2011) Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic. Biol. Med. 51, 2234-2242.
90. Nicolescu, A. C., Ji, Y., Comeau, J. L., Hill, B. C., Takahashi, T., Brien, J. F., Racz, W. J., and Massey, T. E. (2008) Direct mitochondrial dysfunction precedes reactive oxygen species production in amiodar-one-induced toxicity in human peripheral lung epithelial HPL1A cells. Toxicol. Appl. Pharmacol. 227, 370-379.
91. Fromenty, B., Fisch, C., Berson, A., Letteron, P., Larrey, D., and Pessayre, D. (1990) Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J. Pharmacol. Exp. Ther. 255, 1377-1384.
92. Green, D. R., and Reed, J. C. (1998) Mitochondria and Apoptosis. Science 281, 1309-1312.
93. Eguchi, Y., Shimizu, S., and Tsujimoto, Y. (1997) Intracellular ATP Levels Determine Cell Death Fate by Apoptosis or Necrosis. Cancer Res. 57, 1835-1840.
94. Golli-Bennour, E. El, Bouslimi, A., Zouaoui, O., Nouira, S., Achour, A., and Bacha, H. (2012) Cytotoxicity effects of amiodarone on cultured cells. Exp. Toxicol. Pathol. 64, 425-430.
95. Valcheva-Kuzmanova, S. V., Stavreva, G. T., Dancheva, V. Y., Terziev, L. G., Shopova, V. L., and Stoyanova, A. M. (2012) Effect of Aronia Melanocapa fruit juice on the activity of anioxidant enzymes in a rat model of amiodarone-induced pneumotoxicity. J. Biomed. Clin. Res. 5, 97-103.
96. Zamzami, N., and Kroemer, G. (2003) Apoptosis: Mitochondrial Membrane Permeabilization - The (W)hole Story? Curr. Biol. 13, 71-73.
97. Waldhauser, K. M., Brecht, K., Hebeisen, S., Ha, H. R., Konrad, D., Bur, D., and Krähenbühl, S. (2008) Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues. Br. J. Pharmacol. 155, 585-595.
98. Singh, B. N. (1996) Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am. J. Cardiol. 78, 41-53.
99. Sanguinetti, M. C., and Tristani-Firouzi, M. (2006) hERG potassium channels and cardiac arrhythmia. Nature 440, 463-469.
100. Zhang, Y. H., Cheng, H., Alexeenko, V. A., Dempsey, C. E., and Hancox, J. C. (2010) Characterization of recombinant hERG K(+) channel inhibition by the active metabolite of amiodarone desethylamiodarone. J. Electrocardiol. 43, 440-448.
101. Rosenbaum, M. B., Chiale, P. A., Ryba, D., and Elizari, M. V. (1974) Control of tacyarrhythmias with Wolf-Parkinson-White syndrome by amiodaroen hydrochloride. Am. J. Cardiol. 34, 215-223.
102. Rosenbaum, M. B., Chiale, P. A., Halpern, M. S., Nau, G. J., Przybylski, J., Levi, R. J., Lázzari, J. O., and Elizari, M. V. (1976) Clinical efficacy of amiodarone as an antiarrhythmic agent. Am. J. Cardiol. 38, 934-944.
103. Eghbal, M. A., Tafazoli, S., Pennefather, P., and O' Brien, P. J. (2004) Peroxidase catalysed formation of cytotoxic prooxidant phenothiazine free radicals at physiological pH. Chem. Biol. Interact. 151, 43-51.
104. Wen, B., and Zhou, M. (2009) Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. Chem. Biol. Interact. 181, 220-226.
105. Neptune, M., and McCreery, R. L. (1978) Chemical and electrochemical oxidation of 7-hydroxychlorpromazine. J. Med. Chem. 21, 362-368.
106. Watson, R. G., Olomu, A., Clements, D., Waring, R. H., Mitchell, S., and Elias, E. (1988) A proposed mechanism for chlorpromazine jaundice - defective hepatic sulphoxidation combined with rapid hydroxylation. J. Hepatol. 7, 72-78.
107. Thomas, D., Wu, K., Kathöfer, S., Katus, H. A., Schoels, W., Kiehn, J., and Karle, C. A. (2003) The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br. J. Pharmacol. 139, 567-574.
108. Lee, I. S., Park, T. J., Suh, B. C., Kim, Y. S., Rhee, I. J., and Kim, K. T. (1999) Chlorpromazine-induced inhibition of catecholamine secretion by a differential blockade of nicotinic receptors and L-type Ca2+ channels in rat pheochromocytoma cells. Biochem. Pharmacol. 58, 1017-1024.
109. Gupta, A., Lawrence, A. T., Krishnan, K., Kavinsky, C. J., and Trohman, R. G. (2007) Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am. Heart J. 153, 891-899.
110. Reilly, J. G., Ayis, S. A., Ferrier, I. N., Jones, S. J., and Thomas, S. H. L. (2000) QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355 , 1048-1052.
111. Glassman, A. H., and Bigger, J. T. (2001) Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death. Am. J. Psychiatry 158, 1774-1782.
112. Burdock, G. A., Soni, M. G., and Carabin, I. G. (2001) Evaluation of health aspects of kojic acid in food. Regul. Toxicol. Pharmacol. 33, 80-101.
113. Chen, J. S., Wei, C., Rolle, R. S., Otwell, W. S., Balaban, M. O., and Marshall, M. R. (1991) Inhibitory effect of kojic acid on some plant and crustacean polyphenol oxidases. J. Agric. Food Chem. 39, 1396-1401.
114. Chen, J. S., Wei, C., and Marshall, M. R. (1991) Inhibition Mechanism of Kojic Acid on Polyphenol Oxidase. J. Agric. Food Chem. 39, 9-13.
115. Maeda, K., and Fukuda, M. (1991) In vitro effectiveness of several whitening cosmetic components in human melanocytes. J. Soc. Cosmet. Chem. 42, 361-368.
116. Cotellessa, C., Peris, K., Onorati, M. T., Fargnoli, M. C., and Chimenti, S. (1999) The use of chemical peelings in the treatment of different cutaneous hyperpigmentations. Dermatol. Surg. 25, 450-454.
117. Kim, H., Choi, H.-R., Kim, D.-S., and Park, K.-C. (2012) Topical hypopigmenting agents for pigmentary disorders and their mechanisms of action. Ann. Dermatol. 24, 1-6.
118. Kahn, V., Ben-Shalom, N., and Zakin, V. (1997) Effect of Kojic Acid on the Oxidation of N-Acetyldopamine by Mushroom Tyrosinase. J. Agric. Food Chem. 45 , 4460-4465.
119. Moon, K., Ahn, K. S., Lee, J., and Kim, Y. S. (2001) Kojic Acid, a Potential Inhibitor of NF-KB Activation in Transfectant Human HaCaT and SCC-13 Cells. Arch. Pharm. Res. 24, 307-311.
120. Ahn, K. S., Moon, K.-Y., Lee, J., and Kim, Y. S. (2003) Downregulation of NF-innodatak B activation in human keratinocytes by melanogenic inhibitors. J. Dermatol. Sci. 31, 193-201.
121. Niwa, Y., and Akamatsu, H. (1991) Kojic acid scavenges free radicals while potentiating leukocyte functions including free radical generation. Inflammation 15, 303-315.
122. Mitani, H., Koshiishi, I., Sumita, T., and Imanari, T. (2001) Prevention of the photodamage in the hairless mouse dorsal skin by kojic acid as an iron chelator. Eur. J. Pharmacol. 411, 169-174.
123. McBryde, W. A. E., and Atkinson, G. F. (1961) Spectrophotometric study of the reaction between Iron (III) and Kojic acid. Can. J. Chem. 39, 510-525.
124. Fotoohi, A. K., and Albertioni, F. (2008) Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk. Lymphoma 49 , 410-426.
125. Braun, J., and Rau, R. (2009) An update on methotrexate. Curr. Opin. Rheumatol. 21, 216-223.
126. Kremer, J. M. (2008) Methotrexate treatment of rheumatic diseases: can we do better? Arthritis Rheum. 58, 3279-3282.
127. Jolivert, J., and Chabner, B. A. (1983) Intracellular Pharmacokinetics of Methotrexate Polyglutamates in Human Breast Cancer Cells. J. Clin. Invest. 72, 773-778.
128. McGuire, J. J., and Bertino, J. R. (1981) Enzymatic synthesis and function of folylpolyglutamates. Mol. Cell. Biochem. 38, 19-48.
129. Wessels, J. A. M., Huizinga, T. W. J., and Guchelaar, H.-J. (2008) Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 47, 249-255.
130. Allegra, C. J., Hoang, K., Yeh, G. C., Drake, J. C., and Baram, J. (1987) Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. J. Biol. Chem. 262, 13520-13526.
131. Van Triest, B., Pinedo, H. M., Giaccone, G., and Peters, G. J. (2000) Downstream molecular determinants of response to 5- fluorouracil and antifolate thymidylate synthase inhibitors. Ann. Oncol. 11, 385-391.
132. Liu, D.-Y., Lon, H.-K., Wang, Y.-L., DuBois, D. C., Almon, R. R., and Jusko, W. J. (2013) Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen-induced arthritic rats. Biopharm. Drug Dispos. 34, 203-214.
133. Baggott, J. E., Vaughn, W. H., and Hudson, B. B. (1986) Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem. J. 236, 193-200.
134. Chu, E., Drake, J. C., Boarman, D., Baram, J., and Allegra, C. J. (1990) Mechanism of thymidylate synthase inhibition by methotrexate in human neoplastic cell lines and normal human myeloid progenitor cells. J. Biol. Chem. 265, 8470-8478.
135. Matthews, R. G., and Baugh, C. M. (1980) Interactions of pig liver methylenetetrahydrofolate reductase with methylenetetrahydropteroylpolyglutamate substrates and with dihydropteroylpolyglutamate inhibitors. Biochemistry 19, 2040-2045.
136. Baram, J., Chabner, B. A., Drake, J. C., Fitzhugh, A. L., Sholar, P. W., and Allegra, C. J. (1988) Identification and biochemical properties of 10-formyldihydrofolate, a novel folate found in methotrexate-treated cells. J. Biol. Chem. 263, 7105-7111.
137. Bunni, M., Doig, M. T., Donato, H., Kesavan, V., and Priest, D. G. (1988) Role of Methylenetetrahydrofolate Depletion in Methotrex-ate- mediated Intracellular Thymidylate Synthesis Inhibition in Cultured L1210 Cells. Cancer Res. 48, 3398-3404.
138. Baggott, J. E., and Krumdieck, C. L. (1979) Folylpoly-gammaglutamates as Cosubstrates of 10-Formyltetrahydrofolate:5′-Phosphor-ibosyl- 5-amino-4-imidazolecarboxamide Formyltrasferase. Biochemistry 18, 1036-1041.
139. Morrison, P. F., and Allegra, C. J. (1989) Folate cycle kinetics in human breast cancer cells. J. Biol. Chem. 264, 10552-10566.
140. Uraz, S., Tahan, V., Aygun, C., Eren, F., Unluguzel, G., Yuksel, M., Senturk, O., Avsar, E., Haklar, G., Celikel, C., Hulagu, S., and Tozun, N. (2008) Role of ursodeoxycholic acid in prevention of methotrexateinduced liver toxicity. Dig. Dis. Sci. 53, 1071-1077.
141. Jahovic, N., Cevik, H., Sehirli, A. O., Yeʇen, B. C., and Sener, G. (2003) Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J. Pineal Res. 34, 282-287.
142. Sonis, S. T., Elting, L. S., Keefe, D., Peterson, D. E., Schubert, M., Hauer-Jensen, M., Bekele, B. N., Raber-Durlacher, J., Donnelly, J. P., and Rubenstein, E. B. (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100, 1995-2025.
143. Elting, L. S., Cooksley, C., Chambers, M., Cantor, S. B., Manzullo, E., and Rubenstein, E. B. (2003) The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98, 1531-1539.
144. Van den Bongard, D., Mathôt, R., Boogerd, W., Schornagel, J., Soesan, M., Schellens, J., and Beijnen, J. (2001) Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure. Cancer Chemother. Pharmacol. 47, 537-540.
145. Ahmed, Y. A. A. R., and Hasan, Y. (2013) Prevention and Management of High Dose Methotrexate Toxicity. J. Cancer Sci. Ther. 5, 106-112.
146. Widemann, B. C., Balis, F. M., Kempf-Bielack, B., Bielack, S., Pratt, C. B., Ferrari, S., Bacci, G., Craft, A. W., and Adamson, P. C. (2004) High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 100, 2222-2232.
147. Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., Finn, P. W., Collins, L. S., Tumber, A., Ritchie, J. W., Jensen, P. B., Lichenstein, H. S., and Sehested, M. (2007) Determination of the class and isoform selectivity of small molecule histone deacetylase inhibitors. Biochem. J. 409, 581-589.
148. Detich, N., Bovenzi, V., and Szyf, M. (2003) Valproate induces replication-independent active DNA demethylation. J. Biol. Chem. 278, 27586-27592.
149. Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., and Klein, P. S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741.
150. Gurvich, N., Tsygankova, O. M., Meinkoth, J. L., and Klein, P. S. (2004) Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation. Cancer Res. 64, 1079-1086.
151. Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. a, Brill, B., Groner, B., Bach, I., Heinzel, T., and Göttlicher, M. (2003) The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J. 22, 3411-3420.
152. Garcia-Manero, G., Kantarjian, H. M., Sanchez-Gonzalez, B., Yang, H., Rosner, G., Verstovsek, S., Rytting, M., Wierda, W. G., Ravandi, F., Koller, C., Xiao, L., Faderl, S., Estrov, Z., Cortes, J., O'brien, S., Estey, E., Bueso-Ramos, C., Fiorentino, J., Jabbour, E., and Issa, J.-P. (2006) Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108, 3271-3279.
153. Soriano, A. O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., Cortes, J., Wierda, W. G., Ouzounian, S., Quezada, A., Pierce, S., Estey, E. H., Issa, J.-P. J., Kantarjian, H. M., and Garcia-Manero, G. (2007) Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 110, 2302-2308.
154. Braiteh, F., Soriano, A. O., Garcia-Manero, G., Hong, D., Johnson, M. M., Silva, L. D. P., Yang, H., Alexander, S., Wolff, J., and Kurzrock, R. (2008) Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res. 14, 6296-6301.
155. Yang, H., Hoshino, K., Sanchez-Gonzalez, B., Kantarjian, H., and Garcia-Manero, G. (2005) Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid. Leuk. Res. 29, 739-748.
156. Gurvich, N., and Klein, P. S. (2002) Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96, 45-66.
157. Blaheta, R. A., and Cinatl, J., Jr (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev. 22, 492-511.
158. Göttlicher, M., Minucci, S., Zhu, P., Krämer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G., and Heinzel, T. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978.
159. Lampen, A., Siehler, S., Ellerbeck, U., and Go, M. (1999) New Molecular Bioassays for the Estimation of the Teratogenic Potency of Valproic Acid Derivatives in Vitro: Activation of the Peroxisomal Proliferator-Activated Receptor (PPAR-delta). Toxicol. Appl. Pharmacol. 160, 238-249.
160. Loscher, W., and Nau, H. (1985) Pharmacological evaluation of various metabolites and analogues of valproic acid. Neuropharmacology 24, 427-435.
161. Nau, H., and Loxher, W. (1986) Pharmacologic Evaluation of Various Metabolites and Analogs of Valproic Acid: Teratogenic Potencies in Mice. Fundam. Appl. Toxicol. 6, 669-676.
162. Löscher, W. (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58, 31-59.
163. Massart, J., Begriche, K., Buron, N., Porceddu, M., Borgne-Sanchez, A., and Fromenty, B. (2013) Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation and Steatosis. Curr. Pathobiol. Rep. 1, 147-157.
164. Kassahun, K., Farrell, K., and Abbott, F. (1991) Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab. Dispos. 19, 525-535.
165. Silva, M. F. B., Aires, C. C. P., Luis, P. B. M., Ruiter, J. P. N., IJlst, L., Duran, M., Wanders, R. J. A., and Tavares de Almeida, I. (2008) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J. Inherit. Metab. Dis. 31, 205-216.
166. Kleensang, A., Maertens, A., Rosenberg, M., Fitzpatrick, S., Lamb, J., Auerbach, S., Brennan, R., Crofton, K. M., Gordon, B., Fornace, A. J., Gaido, K., Gerhold, D., Haw, R., Henney, A., Ma'ayan, A., McBride, M., Monti, S., Ochs, M. F., Pandey, A., Sharan, R., Stierum, R., Tugendreich, S., Willett, C., Wittwehr, C., Xia, J., Patton, G. W., Arvidson, K., Bouhifd, M., Hogberg, H. T., Luechtefeld, T., Smirnova, L., Zhao, L., Adeleye, Y., Kanehisa, M., Carmichael, P., Andersen, M. E., and Hartung, T. (2014) t4 workshop report: Pathways of Toxicity. ALTEX 31, 53-61.